You are here

The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Johns Hopkins Hospital
Baltimore, Maryland, 21205 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transthyretin-associated Amyloidosis With Polyneuropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patient has amyloid documented by biopsy (in accordance with institutional site
standard of care).

- Patient has documentation of one of the following targeted TTR mutations: Ser77Tyr,
Thr60Ala, Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe, Thr49Ala, Ile107Val, Val30Ala,
Gly47Ala, Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr, Ile107Met. Patients with mutations
other than those listed may be enrolled only after approval by the Sponsor.

- Patient has peripheral and/or autonomic neuropathy and/or cardiomyopathy with a
Karnofsky Performance Status ≥ 50.

- Patient is aged ≥18 to 75 years, inclusive.

- If female, patient is post-menopausal, surgically sterilized, or willing to use two
acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine
device, diaphragm with spermicide, condom with spermicide) throughout the study and
for 3 months from the end of the study. (A condom alone is not considered an
acceptable method of birth control.) If male with a female partner of childbearing
potential, willing to use two acceptable methods of birth control for the duration of
the study. For both females and males, acceptable birth control must be used for at
least 3 months after the last dose of study medication.

- Patient is, in the opinion of the investigator, willing and able to comply with the
study medication regimen and all other study requirements.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than
3-4 times/month (ibuprofen and nimesulide will be permitted).

- Patient has primary or secondary amyloidosis.

- Patient has TTR-associated amyloidosis with V30M mutation.

- If female, patient is pregnant or breast feeding.

- Patient has received prior liver transplantation.

- Patient is expected to undergo liver transplantation within 12 months after
enrollment.

- Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis
C virus (HCV), and/or human immunodeficiency virus (HIV).

- Patient has renal insufficiency (creatinine clearance

- Patient has liver function test abnormalities: alanine transaminases (ALT) and/or
aspartate transaminases (AST) > 2 times upper limit of normal (ULN) that in the
medical judgment of the investigator are due to reduced liver function or active liver
disease.

- Patient has a New York Heart Association (NYHA) Functional Classification ? III.

- Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes
Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse,
and chronic inflammatory diseases).

- Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to
obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g.,
symptomatic left ventricular dysfunction from any cause other than amyloid, patients
with a primary diagnosis of symptomatic valvular heart disease)

- Patient has a co-morbidity anticipated to limit survival to less than 12 months.

- Patient has received an investigational drug/device and/or participated in another
clinical investigational study within 60 days before Baseline (Day 0).

NCT00630864
Pfizer
Completed
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Transthyretin Mutations, Transthyretin Amyloidosis
NCT00628745
All Genders
18+
Years
Multiple Sites
Migraine Without Aura, Migraine With Aura
NCT01859481
All Genders
18+
Years
Multiple Sites
Otitis Media, Otitis Media With Effusion, Pneumococcal Infections
NCT00195611
All Genders
0+
Years
Multiple Sites
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

This is an open-label, multicenter, international study designed to determine TTR stabilization as well as Fx-1006A safety and tolerability, and its effects on clinical outcomes in patients with non-V30M TTR amyloidosis.

Strong pre-clinical and clinical evidence support a daily dose of 20 mg of Fx-1006A to be the optimum dose to achieve stabilization of tetrameric TTR in ATTR-PN patients. Since disease presentation is similar between V30M and non-V30M TTR mutations associated with ATTR-PN and Fx-1006A has been shown to stabilize wild-type and V30M TTR in vitro and ex vivo, the present study is being conducted to determine the effects of Fx-1006A on TTR stabilization in ATTR-PN patients with TTR mutations other than V30M. Safety and exploratory efficacy of Fx-1006A administered once daily for 12 months will also be evaluated in this patient population.

This is an open-label, multicenter, international study designed to determine TTR stabilization as well as Fx-1006A safety and tolerability, and its effects on clinical outcomes in patients with non-V30M TTR amyloidosis. The study will be conducted in two parts. Part 1 will include a six-week dosing period during which all enrolled patients will receive oral Fx-1006A 20 mg soft gelatin capsules once daily for six weeks. At Week 6, blood samples will be collected from each patient to determine TTR stabilization. Patients who complete the Week 6 visit will continue receiving daily oral Fx-1006A 20 mg for up to a total of 12 months during Part 2 of this study. If it is determined that a patient is not stabilized at Week 6, the patient will be discontinued from the study.

During Part 2, clinical outcomes will be measured at Months 6 and 12, based on NIS, Norfolk QOL-DN, mBMI, NCS, HRDB, SF-36, Karnofsky score, and echocardiography; NT-pro-BNP and troponin I levels will be measured at Baseline, Weeks 2 and 6, and Months 3, 6, and 12.

Pharmacokinetic measurements will be made using samples collected at Baseline, Week 6, and Months 6 and 12.

Safety and tolerability will be assessed throughout the study based on vital signs, physical examinations, ECG, echocardiography, 24-hour Holter monitoring, clinical laboratory tests (hematology, serum chemistry, and urinalysis), and monitoring adverse events and concomitant medication use.

Day 1 will be defined as administration of the first dose of study drug. Clinic Visits will be conducted during Screening (Days -30 to -1) and at Baseline (Day 0), and Week 2, and Week 6, and Months 3, 6, and 12 (± 2 weeks of the scheduled date for post-Baseline visits). Monthly telephone contacts (+ 1 week of the scheduled date) will be made during months in which no investigative site visits are scheduled (Months 4, 5, 7, 8, 9, 10, and 11) for assessment of adverse events and concomitant medications. A final telephone contact to assess adverse events and concomitant medication usage will be made 30 days after the last dose of study drug.

Patients who discontinue from the study at any time following enrollment will have a final visit performed, including all safety assessments, at the time of discontinuation. Any patient discontinuing after the Month 6 visit will also have all exploratory assessments performed.

Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Transthyretin-associated Amyloidosis With Polyneuropathy
Drug: Fx-1006A
During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
Experimental: 1
Fx-1006A 20mg soft gelatin capsules once daily for 12 months
Intervention: Drug: Fx-1006A
Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec;6(6):1011-20. doi: 10.1007/s12265-013-9512-x. Epub 2013 Oct 8.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
January 2010
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient has amyloid documented by biopsy (in accordance with institutional site standard of care).
  • Patient has documentation of one of the following targeted TTR mutations: Ser77Tyr, Thr60Ala, Tyr114Cys, Leu58His, Glu89Gln, Ser77Phe, Thr49Ala, Ile107Val, Val30Ala, Gly47Ala, Gly47Glu, Leu55Arg, Lys70Asn, Ile84Thr, Ile107Met. Patients with mutations other than those listed may be enrolled only after approval by the Sponsor.
  • Patient has peripheral and/or autonomic neuropathy and/or cardiomyopathy with a Karnofsky Performance Status ? 50.
  • Patient is aged ?18 to 75 years, inclusive.
  • If female, patient is post-menopausal, surgically sterilized, or willing to use two acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study and for 3 months from the end of the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of childbearing potential, willing to use two acceptable methods of birth control for the duration of the study. For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication.
  • Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.

Exclusion Criteria:

  • Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month (ibuprofen and nimesulide will be permitted).
  • Patient has primary or secondary amyloidosis.
  • Patient has TTR-associated amyloidosis with V30M mutation.
  • If female, patient is pregnant or breast feeding.
  • Patient has received prior liver transplantation.
  • Patient is expected to undergo liver transplantation within 12 months after enrollment.
  • Patient with positive results for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV).
  • Patient has renal insufficiency (creatinine clearance < 30 ml/min).
  • Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST) > 2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease.
  • Patient has a New York Heart Association (NYHA) Functional Classification ? III.
  • Patient has other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases).
  • Patient has prior non-amyloid cardiac disease such as: myocardial infarction due to obstructive coronary artery disease, active non-amyloid cardiomyopathy (e.g., symptomatic left ventricular dysfunction from any cause other than amyloid, patients with a primary diagnosis of symptomatic valvular heart disease)
  • Patient has a co-morbidity anticipated to limit survival to less than 12 months.
  • Patient has received an investigational drug/device and/or participated in another clinical investigational study within 60 days before Baseline (Day 0).
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France,   Germany,   Italy,   United States
 
 
NCT00630864
FX1A-201
B3461022
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Not Provided
Pfizer
January 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now